Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Adverse Drug Reaction Reporting Systems | 4 | 2019 | 694 | 2.05 | Why? |
| Biosimilar Pharmaceuticals | 3 | 2018 | 205 | 1.66 | Why? |
| Pharmacovigilance | 3 | 2020 | 501 | 0.73 | Why? |
| Medication Errors | 1 | 2018 | 107 | 0.69 | Why? |
| Injection Site Reaction | 1 | 2018 | 124 | 0.69 | Why? |
| Publication Bias | 1 | 2016 | 241 | 0.59 | Why? |
| Infliximab | 1 | 2018 | 502 | 0.54 | Why? |
| Papillomavirus Vaccines | 1 | 2019 | 405 | 0.52 | Why? |
| Drug Hypersensitivity | 1 | 2018 | 401 | 0.48 | Why? |
| Disclosure | 1 | 2016 | 423 | 0.46 | Why? |
| Medication Adherence | 2 | 2018 | 1270 | 0.45 | Why? |
| Anti-Inflammatory Agents | 2 | 2020 | 6153 | 0.43 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.40 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.33 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.32 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.31 | Why? |
| Drug Discovery | 1 | 2018 | 3092 | 0.27 | Why? |
| Algorithms | 2 | 2018 | 7346 | 0.26 | Why? |
| Chemical and Drug Induced Liver Injury | 2 | 2018 | 451 | 0.24 | Why? |
| Virus Diseases | 1 | 2020 | 3779 | 0.24 | Why? |
| Risperidone | 1 | 2018 | 55 | 0.19 | Why? |
| Adrenergic beta-1 Receptor Agonists | 1 | 2017 | 6 | 0.18 | Why? |
| Aripiprazole | 1 | 2018 | 60 | 0.18 | Why? |
| Product Surveillance, Postmarketing | 2 | 2018 | 189 | 0.18 | Why? |
| Health Policy | 1 | 2018 | 6242 | 0.18 | Why? |
| Italy | 6 | 2019 | 38444 | 0.17 | Why? |
| Clinical Trials as Topic | 1 | 2016 | 7330 | 0.16 | Why? |
| Vaccination | 2 | 2020 | 19050 | 0.16 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.15 | Why? |
| Glucagon-Like Peptide-1 Receptor | 1 | 2017 | 138 | 0.15 | Why? |
| Health Services Accessibility | 1 | 2018 | 10697 | 0.14 | Why? |
| Databases, Factual | 3 | 2018 | 6248 | 0.13 | Why? |
| Weight Gain | 1 | 2018 | 552 | 0.13 | Why? |
| European Union | 1 | 2017 | 565 | 0.12 | Why? |
| Antidepressive Agents | 1 | 2018 | 509 | 0.12 | Why? |
| National Health Programs | 1 | 2018 | 807 | 0.11 | Why? |
| Drug Interactions | 1 | 2018 | 1653 | 0.11 | Why? |
| Sentinel Surveillance | 1 | 2018 | 1093 | 0.10 | Why? |
| Data Mining | 1 | 2017 | 767 | 0.10 | Why? |
| Antipsychotic Agents | 1 | 2018 | 887 | 0.10 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.10 | Why? |
| Government | 1 | 2018 | 1453 | 0.10 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.09 | Why? |
| Humans | 20 | 2020 | 930598 | 0.09 | Why? |
| Insulin | 1 | 2017 | 1316 | 0.09 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.08 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.08 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.07 | Why? |
| Animals | 3 | 2020 | 78931 | 0.07 | Why? |
| Pharmaceutical Preparations | 1 | 2018 | 1897 | 0.07 | Why? |
| Inpatients | 1 | 2018 | 5161 | 0.06 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.06 | Why? |
| Multiple Sclerosis | 1 | 2017 | 2600 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.06 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.05 | Why? |
| Male | 8 | 2019 | 367725 | 0.05 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.05 | Why? |
| Female | 8 | 2019 | 380317 | 0.05 | Why? |
| Europe | 1 | 2017 | 12702 | 0.05 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3832 | 0.05 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.05 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Nebivolol | 1 | 2017 | 12 | 0.05 | Why? |
| Bisoprolol | 1 | 2017 | 65 | 0.04 | Why? |
| Metoprolol | 1 | 2017 | 42 | 0.04 | Why? |
| Psychoses, Substance-Induced | 1 | 2018 | 91 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Treatment Outcome | 3 | 2018 | 51732 | 0.04 | Why? |
| Half-Life | 1 | 2017 | 298 | 0.04 | Why? |
| Middle Aged | 4 | 2018 | 270681 | 0.04 | Why? |
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 220 | 0.04 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.04 | Why? |
| Child | 3 | 2019 | 70012 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2018 | 12447 | 0.03 | Why? |
| Adolescent | 3 | 2019 | 86841 | 0.03 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.03 | Why? |
| Aged | 3 | 2018 | 215776 | 0.03 | Why? |
| Body Weight | 1 | 2018 | 1074 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.03 | Why? |
| Denmark | 1 | 2017 | 2654 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2017 | 1887 | 0.02 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.02 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.02 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.02 | Why? |
| Depressive Disorder | 1 | 2018 | 1236 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Outpatients | 1 | 2018 | 3417 | 0.02 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.02 | Why? |
| Hypoglycemic Agents | 1 | 2017 | 2165 | 0.02 | Why? |
| Cause of Death | 1 | 2017 | 4823 | 0.02 | Why? |
| Blood Glucose | 1 | 2017 | 3642 | 0.02 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Adult | 1 | 2018 | 244371 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Incidence | 1 | 2018 | 25622 | 0.01 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Retrospective Studies | 1 | 2017 | 105322 | 0.00 | Why? |